* Due to its voluminous nature, entire reference full be made available upon educe

2/26/03

paral No 4 vos90

		Sheet 2 of 2
	AX	Gogu SR, Beckman BS, Wilson RB, et al., "Inhibitory Effects of Zidovudine in Erythroid Progenitor Cells: Reversal with a Combination of Erythropoietin and Interleukin-3," Biochemical Pharmacology, 1995, Vol. 50, pp. 413-9.
01	PE	Goodnough LT, Anderson KC, Kurtz S, et al., "Indications and Guidelines for the Use of Hematopoietic Growth Factors," <i>Transfusion</i> , 1993, Vol. 33, pp. 944-59.
OCT n	AZ C	Harbol AW, Liesveld JL, Simpson-Haidaris PJ, et al., "Mechanisms of Cytopenia in Human Immunodeficiency Virus Infection," <i>Blood Reviews</i> , 1994, Vol. 8, pp. 241-51.
PAREE	2001 BB	Jelkmann WB, Fandrey J, Frede S, et al., "Inhibition of Erythropoietin Production by Cytokines: Implications for the Anemia Involved in Inflammatory States," Annals of the New York Academy of Sciences, 1994, Vol. 718, pp. 300-9.
TRAD	EMBRIT	Jen F, Glue P, Gupta S, et al., "Population Pharmacokinetic and Pharmacodynamic Analysis of Ribavirin in Patients with Chronic Hepatitis C," Therapeutic Drug Monitoring, Vol. 22, No. 3, 2000.
	BD	Koziel MJ, "Cytokines in Viral Hepatitis," Seminars in Liver Disease, 1999, Vol. 19, pp. 157-69.
	BE	Krantz SB, "Erythropoietin," <i>Blood</i> , 1991, Vol. 77, pp. 419-34.
	BF	Kuehl AK, Noormohamed SE, "Recombinant Erythropoietin for Zidovudine-Induced Anemia in AIDS," Annals of Pharmacotherapy, 1995, Vol. 29, pp. 778-9.
	BG	Lai CM, Swaminathan N, Beilharz MW, et al., "Interferon-α Inhibits Erythropoietin-Induced Proliferation, but Not Differentiation, and Restricts Erythroleukemia Development," Journal of Interferon & Cytokine Research, 1995, Vol. 15, pp. 669-75.
	вн	MacDougall DS, "Recombinant Human Erythropoietin for HIV-Related Anemia," Journal of the Int'l Association of Physicians in AIDS Care, Oct. 1998, pp. 18-24.
	Ві	Marcellin P, Boyer N, Giostra E, et al., "Recombinant Human α-Interferon in Patients with Chronic Non-A, Non-B Hepatitis: A Multicenter Randomized Controlled Trial from France." Hepatology, 1991, Vol. 13, pp. 393-7.
	ВЈ	McHutchison JG, Gordon SC, Schiff ER, et al., "Interferon Alfa-2b Alone or in Combination With Ribavirin as Initial Treatment for Chronic Hepatitis C," New England Journal of Medicine, 1998, Vol. 339, pp. 1485-92.
	вк	Means RT, Jr., "Advances in the Anemia of Chronic Disease," Int'l Journal of Hematology, 1999, Vol. 70, pp. 7-12.
	BL	Means RT, Jr., "Pathogenesis of the Anemia of Chronic Disease: A Cytokine-Mediated Anemia," Stem Cells, 1995, Vol. 13, pp. 32-7.
	ВМ	Means RT, Jr., Krantz SB, "Progress in Understanding the Pathogenesis of the Anemia of Chronic Disease," Blood, 1992, Vol. 80, pp. 1639-47.
	BN	Moore RD, Keruly JC, Chaisson RE, "Anemia and Survival in HIV Infection," Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 1998, Vol. 19, pp. 29-33.
	во	Musto P, Falcone A, D'Arena G, et al., "Clinical Results of Recombinant Erythropoietin in Transfusion-Dependent Patients with Refractory Multiple Myeloma: Role of Cytokines and Monitoring of Erythropoiesis," European Journal of Haematology, 1997, Vol. 58, pp. 314-9.
	ВР	Napoli J, Bishop GA, McGuinness PH, et al., "Progressive Liver Injury in Chronic Hepatitis C Infection Correlates with Increased Intrahepatic Expression of Th1-Associated Cytokines," <i>Hepatology</i> , 1996, Vol. 24, pp. 759-65.
	BQ	Peeters HM, Jongen-Lavrencic M, Vreugdenhil G, et al., "Effect of Recombinant Human Erythropoietin on Anemia and Disease Activity in Patients with Rheumatoid Arthritis and Anaemia of Chronic Disease: A Randomised Placebo Controlled Double Blind 52 Weeks Clinical Trial," Annals of the Rheumatic Diseases, 1996, Vol. 55, pp. 739-44.
	BR	Poynard T, Marcellin P, Lee SS, et al., "Randomised Trial of Interferon o2b Plus Ribavirin for 48 Weeks or For 24 Weeks Versus Interferon o2b Plus Placebo for 48 Weeks for Treatment of Chronic Infection with Hepatitis C Virus," <i>Lancet</i> , 1998, Vol. 352, pp. 1426-32.
	BS	Reichard O, Norkrans G, Fryden A, et al., "Randomized, Double-Blind, Placebo-Controlled Trial of Interferon α-2b With and Without Ribavirin for Chronic Hepatitis C," Lancet, 1998, Vol. 351, pp. 83-7.
	ВТ	Reichard O, Schvarcz R, Weiland O., "Therapy of Hepatitis C: Alpha Interferon and Ribavirin," Hepatology, 1997, Vol. 26 (Supp. 1), pp. 108S-11S.
	BU	Spivak JL, Barnes DC, Fuchs E, et al., "Serum Immunoreactive Erythropoietin in HIV-Infected Patients, Journal of the American Medical Association, 1989, Vol. 261, pp. 3104-7.
7	BV	Thomas HC, Booth J, Brown J., "Pathophysiology and Treatment of Hepatitis C," Drugs, 1996, Vol. 52 (Supp. 2), pp. 1-8.
	BW	Weisz K, Goldman D, Talal A, et al., "Interferon (IFN) and Ribavirin (RBV) Therapy for Hepatitis C (HCV) in HIV-Coinfected Patients, 12 Month Follow Up," 7th Conference on Retroviruses and Opportunistic Infections, Jan. 30-Feb. 2, 2000, Abstract 283.
0.10	BX	"Management of Hepatitis C Consensus Development Statement," National Institutes of Health, Mar. 24-26, 1997.
KKV)	ВУ	"Rebetron Product Label," Physician's Desk Reference, 53rd Ed., Medical Economics Company, Montvale, NJ, 1999.
EXAMINER	PRM.	DATE CONSIDERED 2/26/03
		ce considered, whether or not citation is in conformance with MPEP 609. Draw line through d not considered. Include copy of this form with next communication to applicant.

paper 10.14